Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin.

Takano M, Ikeda Y, Kudoh K, Kita T, Sasaki N, Kikuchi Y.

J Obstet Gynaecol Res. 2013 Apr;39(4):872-5. doi: 10.1111/j.1447-0756.2012.02047.x. Epub 2012 Nov 20.

PMID:
23167774
2.

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.

Krasner CN, McMeekin DS, Chan S, Braly PS, Renshaw FG, Kaye S, Provencher DM, Campos S, Gore ME.

Br J Cancer. 2007 Dec 17;97(12):1618-24. Epub 2007 Nov 13.

3.

Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 cases.

Ikeda Y, Takano M, Oda K, Kouta H, Goto T, Kudoh K, Sasaki N, Kita T, Kikuchi Y.

Int J Gynecol Cancer. 2013 Feb;23(2):355-60. doi: 10.1097/IGC.0b013e31827de69e.

PMID:
23358182
4.
5.

A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.

Wenham RM, Lapolla J, Lin HY, Apte SM, Lancaster JM, Judson PL, Gonzalez-Bosquet J, Herschberger A, Havrilesky LJ, Secord AA.

Gynecol Oncol. 2013 Jul;130(1):19-24. doi: 10.1016/j.ygyno.2013.04.049. Epub 2013 Apr 25.

PMID:
23623830
6.

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.

Monk BJ, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita AS, Nieto A, Park YC, Cheng PS, Li W, Favis R, Ricci D, Poveda A.

Ann Oncol. 2015 May;26(5):914-20. doi: 10.1093/annonc/mdv071. Epub 2015 Feb 26.

PMID:
25722380
7.

Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.

Kawano M, Mabuchi S, Kishimoto T, Hisamatsu T, Matsumoto Y, Sasano T, Takahashi R, Sawada K, Takahashi K, Takahashi T, Hamasaki T, Kimura T.

Int J Gynecol Cancer. 2014 Jun;24(5):829-37. doi: 10.1097/IGC.0000000000000143.

PMID:
24844217
8.

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I.

J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17. Erratum in: J Clin Oncol. 2014 Dec 10;32(35):4025.

PMID:
24637997
9.

Trabectedin and ovarian cancer: statistical trickery.

[No authors listed]

Prescrire Int. 2011 Apr;20(115):93. No abstract available.

PMID:
21648209
10.

A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).

Raez LE, Santos ES, Webb RT, Wade J, Brito RA, Karr M, Kennah A, Childs BH.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1103-10. doi: 10.1007/s00280-013-2301-z. Epub 2013 Sep 22.

PMID:
24057043
11.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.

Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N, Lebedinsky C, Parekh T, Gómez J, Park YC, Alfaro V, Monk BJ.

Ann Oncol. 2011 Jan;22(1):39-48. doi: 10.1093/annonc/mdq352. Epub 2010 Jul 19.

12.

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM.

J Clin Oncol. 2010 Jul 1;28(19):3107-14. doi: 10.1200/JCO.2009.25.4037. Epub 2010 Jun 1.

PMID:
20516432
13.

Bevacizumab, Carboplatin and Paclitaxel Combination Treatment in Advanced Stage Ovarian Cancer: The First Experience in Thammasat University Hospital, Thailand: A Case Report.

Suwannarurk K, Thaweekul Y, Mairaing K, Poomtavorn Y, Tangtiang K, Piyawang W, Bhamarapravatana K.

J Med Assoc Thai. 2015 Apr;98 Suppl 3:S121-5.

PMID:
26387399
14.
15.

A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.

Leporini C, Patanè M, Saullo F, Rende P, Gallelli L, Di Paola ED, Toscano R, Lucia M, Rossi M, De Sarro G, Russo E.

BioDrugs. 2014 Dec;28(6):499-511. doi: 10.1007/s40259-014-0100-7. Review.

PMID:
25209722
16.

The efficacy of trabectedin in treating ovarian cancer.

Teplinsky E, Herzog TJ.

Expert Opin Pharmacother. 2017 Feb;18(3):313-323. doi: 10.1080/14656566.2017.1285282. Review.

PMID:
28140689
17.

Trabectedin: Supportive care strategies and safety profile.

Jordan K, Jahn F, Jordan B, Kegel T, Müller-Tidow C, Rüssel J.

Crit Rev Oncol Hematol. 2015 Jun;94(3):279-90. doi: 10.1016/j.critrevonc.2015.02.012. Epub 2015 Mar 6. Review.

PMID:
25794812
18.

New agents and new formulations for the treatment of ovarian cancer.

Sabbatini P.

Clin Adv Hematol Oncol. 2005 Nov;3(11):840-2. No abstract available.

PMID:
16491624
19.

Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.

Li Y, Yang Y, Shang YM, Zheng H.

Indian J Cancer. 2014 Mar;51 Suppl 3:e92-4. doi: 10.4103/0019-509X.154079.

20.

Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.

Bendell JC, Tournigand C, Swieboda-Sadlej A, Barone C, Wainberg ZA, Kim JG, Pericay C, Pastorelli D, Tarazi J, Rosbrook B, Bloom J, Ricart AD, Kim S, Sobrero AF.

Clin Colorectal Cancer. 2013 Dec;12(4):239-47. doi: 10.1016/j.clcc.2013.09.001.

PMID:
24188685

Supplemental Content

Support Center